Nuvation Bio
$4.85
72
+$0.15+3.19% Tuesday 20:00
Statistics
Day High
4.91
Day Low
4.72
52W High
9.75
52W Low
1.57
Volume
2,089,569
Avg. Volume
4,804,778
Mkt Cap
1.66B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
19MayExpected
Expected EPS
0.008687
Actual EPS
N/A
Financials
-7,213.76%Profit Margin
Unprofitable15.75MRevenue
-1.14BNet Income
Analyst Ratings
11.57Average Price Target
The highest estimate is 17.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy 71%
Hold 29%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow NUVB. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap119.69B
Merck
MRK
Mkt Cap300.2B
Pfizer
PFE
Mkt Cap153.13B
Gilead Sciences
GILD
Mkt Cap172.51B
AMGEN
AMGN
Mkt Cap189.22B
Abbvie
ABBV
Mkt Cap367.8B
Regeneron Pharmaceuticals
REGN
Mkt Cap79.17B
Astrazeneca
AZN
Mkt Cap316.3B
Novartis
NVS
Mkt Cap297.35B
Johnson & Johnson
JNJ
Mkt Cap574.66B
About
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
Show more...
CEO
Dr. David T. Hung M.D.
Employees
273
Country
United States
ISIN
US67080N1019
Listings
0 Comments
Share your thoughts
FAQ
What is Nuvation Bio stock price today?▼
The current price of NUVB is $4.85 USD — it has increased by +3.19% in the past 24 hours. Watch Nuvation Bio stock price performance more closely on the chart.
What is Nuvation Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Nuvation Bio stocks are traded under the ticker NUVB.
Is Nuvation Bio stock price growing?▼
NUVB stock has risen by +7.06% compared to the previous week, the month change is a +9.23% rise, over the last year Nuvation Bio has showed a +140.1% increase.
What is Nuvation Bio market cap?▼
Today Nuvation Bio has the market capitalization of 1.66B
When is the next Nuvation Bio earnings date?▼
Nuvation Bio is going to release the next earnings report on May 19, 2026.
What were Nuvation Bio earnings last quarter?▼
NUVB earnings for the last quarter are -0.11 USD per share, whereas the estimation was -0.09 USD resulting in a -23.6% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Nuvation Bio revenue for the last year?▼
Nuvation Bio revenue for the last year amounts to 15.75M USD.
What is Nuvation Bio net income for the last year?▼
NUVB net income for the last year is -1.14B USD.
How many employees does Nuvation Bio have?▼
As of April 15, 2026, the company has 273 employees.
In which sector is Nuvation Bio located?▼
Nuvation Bio operates in the Health & Wellness sector.
When did Nuvation Bio complete a stock split?▼
Nuvation Bio has not had any recent stock splits.
Where is Nuvation Bio headquartered?▼
Nuvation Bio is headquartered in New York, United States.